Research graph
References from A Phase I Study of Nimotuzumab Combined with Irinotecan in Chinese Patients with Advanced Solid Tumors. Local targets link to admitted publications; unresolved targets remain external evidence.
The ErbB/HER family of protein‐tyrosine kinases and cancer
10.1016/j.phrs.2013.11.002 · 2014 · External reference
Antitumour immunity regulated by aberrant ERBB family signalling
10.1038/s41568-020-00322-0 · 2021 · External reference
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
10.1016/j.bioorg.2020.103811 · 2020 · External reference
Targeted peptide‐Au cluster binds to epidermal growth factor receptor (EGFR) in both active and inactive states: a clue for cancer inhibition through dual pathways
10.1016/j.scib.2018.02.007 · 2018 · External reference
Immune responses to epidermal growth factor receptor (EGFR) and their application for cancer treatment
10.3389/fphar.2016.00405 · 2016 · External reference
Epidermal growth factor receptor (EGFR) status and K‐Ras mutations in colorectal cancer
10.1093/annonc/mdn416 · 2008 · External reference
Epidermal growth factor receptor (EGFR)‐targeted therapies in mesothelioma
10.1080/17425247.2019.1598374 · 2019 · External reference
A phase Ib/II study of afatinib in combination with nimotuzumab in non‐small cell lung cancer patients with acquired resistance to gefitinib or erlotinib
10.1158/1078-0432.ccr-15-1653 · 2016 · External reference
Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: a humanized anti‐EGFR antibody
10.1002/ijc.10647 · 2002 · External reference
Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non‐small cell lung cancer cell lines of differing epidermal growth factor receptor status
10.1038/sj.bjc.6604222 · 2008 · External reference
Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile
10.4161/cbt.11.4.14097 · 2011 · External reference
Nimotuzumab: evidence of clinical benefit without rash
10.1634/theoncologist.10-9-760 · 2005 · External reference
Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation
10.1158/0008-5472.can-08-4518 · 2009 · External reference
Nimotuzumab, an EGFR‑targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma
2020 · External reference
Nimotuzumab Plus Gemcitabine for K‐Ras Wild‐Type Locally Advanced or Metastatic Pancreatic Cancer
10.1200/jco.22.02630 · 2023 · External reference
A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors
10.1007/s00280-013-2277-8 · 2013 · External reference
A dose‐escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies
10.1007/s10637-010-9444-0 · 2011 · External reference
Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan
10.1007/s00381-017-3409-y · 2017 · External reference
Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion
10.1002/pst.326 · 2009 · External reference
Clinical pharmacology of the antibody–drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors
10.1007/s40262-024-01369-0 · 2024 · External reference
Semi‐mechanistic pharmacokinetic model to guide the dose selection of nimotuzumab in patients with autosomal dominant polycystic kidney disease
10.3390/pharmaceutics12121147 · 2020 · External reference
Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer
10.1002/jcph.496 · 2015 · External reference
Half‐life extended biotherapeutics
10.1517/14712598.2016.1165661 · 2016 · External reference
The practical importance of half‐life in psychopharmacology
10.4088/jcp.22f14584 · 2022 · External reference
Pharmacokinetic study of the humanized anti‐EGF‐receptor monoclonal antibody nimotuzumab in combination with gemcitabine in patients (Pts) with locally advanced or metastatic pancreatic cancer (PC)
2007 · External reference
A phase I study of the humanized anti‐epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM‐h‐R3 (nimotuzumab) in patients with advanced solid tumors
10.1200/jco.2006.24.18_suppl.13054 · 2006 · External reference
A randomised, open label phase III trial with nimotuzumab, an anti‐epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
10.1016/j.ejca.2014.12.019 · 2015 · External reference
Hematological toxicities of concurrent chemoradiotherapies in head and neck cancers: comparison among cisplatin, nedaplatin, lobaplatin, and nimotuzumab
10.3389/fonc.2021.762366 · 2021 · External reference
Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation
2008 · External reference
Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy
10.1634/theoncologist.2010-0298 · 2011 · External reference
Nimotuzumab: a novel anti‐EGFR monoclonal antibody that retains anti‐EGFR activity while minimizing skin toxicity
10.1517/14712590903110709 · 2009 · External reference
Nimotuzumab: beyond the EGFR signaling cascade inhibition
10.1053/j.seminoncol.2018.04.008 · 2018 · External reference
Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation
10.1158/2159-8290.cd-16-0050 · 2016 · External reference
